Dosing regimen matters: The importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2795-2805

  Martinez, Marilyn N ^a   Papich, Mark G ^b   Drusano, George L ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANHYDROCHLORTETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHLORTETRACYCLINE; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; FLORFENICOL; GARENOXACIN; GATIFLOXACIN; GENTAMICIN; LINEZOLID; MONOBACTAM DERIVATIVE; OXACILLIN; PENICILLIN G; QUINOLONE DERIVATIVE; SULFONAMIDE; TEICOPLANIN; TELITHROMYCIN; THIAMPHENICOL; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EXPOSURE; DRUG MEGADOSE; EARLY INTERVENTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INOCULATION; MAXILLA SINUSITIS; META ANALYSIS (TOPIC); METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS; SHORT SURVEY; STEADY STATE; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY INTERVENTION (EDUCATION); HUMANS;

EID: 84861134871     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05360-11     Document Type: Short Survey

References (61)

1. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82- 85.
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79 - 86.
3. Ambrose PG, et al. 2004. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin. Infect. Dis. 38:1513-1520. (Pubitemid 38738543)
4. Baquero F, Negri MC. 1997. Strategies to minimize the development of antibiotic resistance. J. Chemother. 9(Suppl):29 -37.
5. Bayles KW. 2000. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol. 8:274 -278.
6. Bigger JW. 1944. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244:497-500.
7. Blaser J, Stone BB, Groner MC, Zinner SH. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob. Agents Chemother. 31: 1054-1060. (Pubitemid 17099578)
8. Blasi F, Tarsia P. 2005. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int. J. Antimicrob. Agents 26(Suppl 3):S148 -S155.
9. Blondeau JM. 2009. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet. Dermatol. 20:383-396.
10. Bow EJ. 2011. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr. Opin. Infect. Dis. 24:545-553.
11. CLSI. 2008. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-third edition. CLSI document M31-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
12. CLSI. 2011 Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
14. Craig WA, Dalhoff A. 1998. Pharmacodynamics of fluoroquinolones in experimental animals, p 208-232. In Born GV, et al. (ed), Handbook of experimental pharmacology. Springer Verlag, Berlin, Germany.
15. Davis BD, Chen LL, Tai PC. 1986. Misread protein creates membrane channels: an essential step in bactericidal action of aminoglycosides. Proc. Natl. Acad. Sci. U. S. A. 83:6164-6168. (Pubitemid 16000673)
16. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289 -300.
17. Drusano GL, Johnson DE, Rosen M, Standiford HC. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490. (Pubitemid 23072592)
18. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob. Agents Chemother. 53:2266 -2273.
19. Drusano GL, Liu W, Brown DL, Rice LB, Louie A. 2009. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J. Infect. Dis. 199:219 -226.
20. Dunbar LM, et al. 2004. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 20:555-563. (Pubitemid 38525164)
21. Dunbar LM, et al. 2003. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37:752-760. (Pubitemid 37153652)
22. El Garch F, et al. 2010. Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:2076 -2082.
23. el Moussaoui R, et al. 2006. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 332:1355.
24. Epstein BJ, Bums JG, Drlica K. 2004. The changing face of antibiotic prescribing: the mutation selection window. Ann. Pharmacother. 38: 1675-1681.
25. Erlendsdottir H, et al. 2001. Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob. Agents Chemother. 45:1078 -1085.
26. Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob. Agents Chemother. 52:1924 -1928.
27. Firsov AA, et al. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604 -1613.
28. Gefen O, Gagay C, Mumcuoglu M, Engel G, Balaban NQ. 2008. Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Proc. Natl. Acad. Sci. U. S. A. 105:6145- 6149.
29. Handel A, Margolis E, Levin BR. 2009. Exploring the role of the immune response in preventing antibiotic resistance. J. Theor. Biol. 256:655- 662.
30. Hooper DC. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341. (Pubitemid 32374357)
31. Jayaraman R. 2008. Bacterial persistence: some new insights into an old phenomenon. J. Biosci. 33:795- 805.
32. Jumbe N, et al. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285. (Pubitemid 38056363)
33. Jumbe NL, et al. 2006. Quinolone efflux pumps play a central role in emergence of fluoroquinolones resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310 -317.
34. Kaki R, et al. 2011. Impact of antimicrobial stewardship in critical care: a systematic review. J. Antimicrob. Chemother. 66:1223-1230.
35. Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, Rafailidis PI, Falagas ME. 2009. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch. Dis. Child. 94:607- 614.
36. König C, Simmen HP, Blaser J. 1998. Bacterial concentrations in pus and infected peritoneal fluid-implications for bactericidal activities of antibiotics. J. Antimicrob. Chemother. 42:227-232. (Pubitemid 28393592)
37. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48 -56.
38. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322:107-131.
39. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372.
40. Li XZ, Nikaido H. 2009. Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555-1623.
41. Lipsitch M, Levin BR. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373. (Pubitemid 27111032)
42. Martinez M, Silley P. 2010. Antimicrobial drug resistance. Handb. Exp. Pharmacol. 199:227-264.
43. Molyneux E, et al. 2011. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 377:1837-1845.
44. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601- 607.
45. Moyed HS, Broderick SH. 1986. Molecular-cloning and expression of hipA, a gene of Escherichia-coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 166:399-403. (Pubitemid 16112134)
46. Nicolau DP, et al. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
47. Pagès JM, James CE, Winterhalter M. 2008. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6:893-903.
48. Pugh RJ, Cooke RP, Dempsey G. 2010. Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. J. Hosp. Infect. 74:337-343.
49. Pugh R, Grant C, Cooke RP, Dempsey G. 2011. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst. Rev. 10:CD007577.
50. Scaglione F, et al. 2009. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur. Respir. J. 34: 394-400.
51. Scalera NM, File TM, Jr. 2007. How long should we treat community-acquired pneumonia? Curr. Opin. Infect. Dis. 20:177-181. (Pubitemid 46340801)
52. Schrag SJ, et al. 2001. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286: 49-56. (Pubitemid 32606331)
53. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. 2006. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir. Med. 100: 2129-2136.
54. Smirnova MV, et al. 2009. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J. Antimicrob. Chemother. 64:815-820.
55. Snape MD, Kelly DF. 2011. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 377:1809 -1810.
56. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51: 744-747. (Pubitemid 46185299)
57. Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
58. Walsh C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781.
59. Zhao X, Drlica K. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl 3):S147-S156. (Pubitemid 32835784)
60. Zhao X, Drlica K. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565. (Pubitemid 34142821)
61. Zhao X, Drlica K. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436.